Nan Ji (PAQ Therapeutics)

Dis­cov­ery by Shang­hai sci­en­tists in­spires new plan of AT­TEC for pro­tein degra­da­tion

In a re­view penned weeks ago, Craig Crews — the Yale sci­en­tist cred­it­ed with the dis­cov­ery of PRO­TACs — re­flect­ed on how, in the two decades since he helped launch the field, tar­get­ed pro­tein degra­da­tion has moved be­yond the pro­tea­some in­to “nov­el and ex­cit­ing” strate­gies.

“For ex­am­ple, Lyso­some Tar­get­ing Chimeras (LY­TACs) har­ness the lyso­so­mal degra­da­tion path­way to in­duce degra­da­tion of ex­tra­cel­lu­lar pro­teins and the Macroau­tophagy Degra­da­tion Tar­get­ing Chimera (MAD­TAC) plat­forms, AU­TACs and AT­TECs hi­jack the au­tophagy path­way, thus po­ten­tial­ly en­abling the tar­get­ed de­struc­tion of en­tire or­ganelles and pro­tein ag­gre­gates,” he and co-au­thor Michael Bond wrote.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.